Key result
An early invasive strategy (<24 h) did not reduce 30-day MACEs compared to a delayed strategy (≥24 h), though any angiography reduced MACEs versus none.
Why the study?
Although an invasive strategy within 24 hours is recommended for NSTEMI patients, the optimal timing of the invasive strategy remains controversial.
Does early coronary angiography (<24 h) reduce major adverse cardiac events within 30 days in patients with NSTEMI compared to delayed angiography (≥24 h)?
Cohort (n=969)
Yes
Does early coronary angiography (<24 h) reduce major adverse cardiac events within 30 days in patients with NSTEMI compared to delayed angiography (≥24 h)?
In a real-world Chinese registry of NSTEMI patients, an early invasive strategy (<24 hours) did not reduce 30-day MACEs or mortality compared to a delayed strategy, though undergoing angiography at any time was associated with better outcomes than no angiography.
Answers are grounded in this paper and cite their sources.
Early invasive strategy showed no short-term outcome benefit in NSTEMI; leaves open optimal timing and requires prospective trials.
Objective Although an invasive strategy has been recommended within 24 h for patients with non-ST-segment elevation myocardial infarction (NSTEMI), the optimal timing of the invasive strategy remains controversial. We sought to investigate the association between the different timings of invasive strategies and clinical outcomes in patients with NSTEMI. Materials and methods Patients admitted with NSTEMI from the Evaluation and Management of Patients with Acute ChesT pain in China (EMPACT) registry between January 2016 and September 2017 were included. The primary outcomes were major adverse cardiac events (MACEs) within 30 days. Multivariable logistic regression was performed to assess independent risk factors for MACEs. Results A total of 969 patients with NSTEMI from the EMPACT Registry were eligible for this study. Coronary angiography (CAG) was performed in 501 patients [<24 h, n = 150 (15.5%); ≥ 24 h, n = 351 (36.2%)]. The rate of MACEs at 30 days in all patients was 9.2%, including 54 (5.6%) deaths. Patients who underwent CAG had a lower rate of MACEs and mortality than those who did not receive CAG (MACEs: 5.6% vs. 13.0%, P < 0.001; mortality: 1.6% vs. 9.8%, P < 0.001). Nonetheless, no statistically significant difference was found in the rates of MACEs and mortality between the early (< 24 h) and delayed (≥ 24 h) CAG groups. Older age (OR: 1.036, 95% CI: 1.007, 1.065, P = 0.014), and acute heart failure (OR: 2.431, 95% CI: 1.244, 4.749, P = 0.009) increased the risk of MACEs and protective factors were underwent CAG (OR: 0.427, 95% CI: 0.219, 0.832, P = 0.012) or PCI (OR: 0.376, 95% CI: 0.163, 0.868, P = 0.022). In the multilevel logistic regression, older age (OR: 0.944, 95% CI: 0.932, 0.957, P < 0.001), cardiogenic shock (OR: 0.233, 95% CI: 0.079, 0.629, P = 0.009), pulmonary moist rales (OR: 0.368, 95% CI: 0.197, 0.686, P = 0.002), and prior chronic kidney disease (OR: 0.070, 95% CI: 0.018, 0.273, P < 0.001) was negatively associated with CAG. Conclusion This real-world cohort study of NSTEMI patients confirmed that the early invasive strategy did not reduce the incidence of MACEs and mortality within 30 days compared with the delayed invasive strategy in NSTEMI patients.
No takes yet. Share an insight, caveat, or question.
Han et al. (2022) conducted a cohort in Non-ST-segment elevation myocardial infarction (NSTEMI) (n=969). Early invasive strategy (< 24 h) vs. Delayed invasive strategy (≥ 24 h) was evaluated on Major adverse cardiac events (MACEs) within 30 days. An early invasive strategy (<24 h) did not reduce 30-day MACEs compared to a delayed strategy (≥24 h), though any angiography reduced MACEs versus none.
Synapse has enriched 10 related papers. Consider them for comparative context: